

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

Serial No.

02-192

09/849,115

RECEIVED

APR 26 2002

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)



Applicant:

TECH CENTER 1600/2900

Progulske-Fox, et al.

Filing Date:

Group:

May 5, 2001

1645

U.S. PATENT DOCUMENTS



Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
<i>aw</i>	1.	5,824,791	10/20/98	Progulske-Fox, et al.	536	237	12/11/95
	2.	5,830,710	11/03/98	Progulske-Fox, et al.	435	911	12/09/94
	3.	6,031,072	02/29/00	Blaschuk, et al.	530	317	07/11/97
	4.	6,110,747	08/29/00	Blaschuk, et al.	436	512	12/29/98
	5.	6,169,071 B1	01/02/01	Blaschuk, et al.	514	4	12/23/97

FOREIGN PATENT DOCUMENTS


		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
<i>aw</i>	6.	9 9 6 0 9 8 4	12/02/99	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

<i>aw</i>	7.	Eckhardt, et al., "A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium", <i>Annals of Oncology</i> 7:419-496, 1996
	8.	Irie, et al., "Inhibition of Attachment and Chemotactic Invasion of Uterine Endometrial Cancer Cells by a New Vinca Alkaloid, Conophylline", <i>Anticancer Research</i> , 19:3061-3066, 1999
	9.	Fidler, et al., "The Implications of Angiogenesis for the Biology and Therapy of Cancer Metastasis", <i>Cell</i> , Vol. 79, 185-188, 1994
	10.	Stupack, et al., "ECM Remodeling Regulates Angiogenesis: Endothelial Integrins Look for New Ligands", <i>Science's stke</i> , p. 1-6, 2002



1. Chen, et al., "A Strategy to Discover Circulating Angiogenesis Inhibitors Generated by Human Tumors", *Cancer Research*, 55:423-4233, 1995
12. O'Reilly, et al., "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth", *Cell*, Vol. 98, p. 277-285, 1997
13. Yamaguchi, et al., "Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding", *The EMBO Journal*, Vol. 18, pp. 4414-4423, 1999
14. Vitale, et al., "Apoptosis induced by denied adhesion to extracellular matrix *anoikis) in thyroid epithelial cells is p53 dependent but fails to correlate with modulation of p53 expression", *FEBS Letters* 462:57-60, 1999
15. Attwell, et al., "The integrin-linked kinase (ILK) suppresses anoikis", *Oncogene* 19(33):3811-15, 2002
16. Rosen, et al., "Activated ras Prevents Downregulation of Bcl-X_L Triggered by Detachment from the Extracellular Matrix: A Mechanism of ras-induced Resistance to Anoikis in Intestinal Epithelial Cells", *The Journal of Cell Biology*, Vol. 149, No. 2, pp. 447-455, 2000
17. Rytömaa, et al., "Involvement of FADD and caspase-8 signaling in detachment-induced apoptosis", *Current Biology*, Vol. 9, No. 18, pp. 1043-1046, 1999
18. Erdreich-Epstein, et al., "Integrins $\alpha\beta_3$ and $\alpha\beta_5$ are Expressed by Endothelium of High-Risk Neuroblastoma and Their Inhibition is Associated with Increased Endogenous Ceramide", *Cancer Research*, 60, 712-721, 2000
19. Lee, et al., " $\alpha_5\beta_1$ Integrin Protects Intestinal Epithelial Cells from Apoptosis through a Phosphatidylinositol 3-Kinase and Protein Kinase B-dependent Pathway", *Molecular Biology of the Cell*, Vol. 11, pp 1973-1987, 2000
20. Kawahara, et al., "Inhibitory effects of adhesion oligopeptides on the invasion of squamous carcinoma cells with special reference to implication of α_v integrins", *J. Cancer Res. Clin. Oncol.*, 121:133-140, 1995
21. Ruoslahti, "Integrins as signaling molecules and targets for tumor therapy", *Kidney International*, Vol. 51, pp. 1413-1417, 1997
22. Brassard, et al., "Integrin $\alpha\beta_3$ -Mediated Activation of Apoptosis", *Experimental Cell Research* 251, pp. 33-45, 1999
23. Kottke, et al., "Comparison of Paclitaxel-, 5-Fluoro-2'-deoxyuridine-, and Epidermal Growth Factor (EGF)-induced Apoptosis", *The Journal of Biological Chemistry*, Vol. 274, No. 22, pp. 15927-15936, 1999
24. Dark, et al., "Combretastain A-4, an Agent that Displays Potent and Selective Toxicity toward Tumor Vasculature", *Cancer Res.*, Vol. 57, pp. 1829-1834, 1997
25. Taddei, et al., "Inhibitory Effect of Full-Length Human Endostatin on in Vitro Angiogenesis", *Biochemical and Biophysical Research Communications*, 263, pp. 340-345, 1999
26. Albini, et al, "Somatostatin controls Kaposi's sarcoma tumor growth through inhibition of angiogenesis", *The FASEB Journal*, Vol. 13, pp. 647-655, 1999
27. Stack, et al., "Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation", *Biochem. J.*, 340, pp. 77-84, 1999
28. Layman, "Angiosuppressive Protein from *P. Gingivalis*", Abstract,
29. Paramaesvaran, et al., "Vascular disruption by a 15kDa adhesin domain from *Porphyromonas gingivalis*", *J. Dental Res.*, 77:664, 1998
30. Phillips, et al., "Alterations in cell morphology and cytoskeletal proteins in gingival fibroblasts exposed to a *Bacteroides gingivalis* extract", *J. Periodont. Res.*, 25:339-346, 1990



31. Baba, et al., "Anti-angiogenesis agent DS-4152 is a potent and selective inhibitor of HIV-1 replication in vitro", *AIDS*, Vol. 8, No. 1, pp.43-48, 1994
32. Wu, et al, "Bacteroides fragilis enterotoxin cleaves the zonula adherens protein, E-cadherin", *Natl. Acad. Sci. USA*, Vol. 95, pp. 14979-14984, 1998
33. Hecht, et al., "Clostridium difficile Toxin A Perturbs Cytoskeletal Structure and Tight Junction Permeability of Cultured Human Intestinal Epithelial Monolayers", *J. Clin. Invest.*, Vol. 82, pp. 1516-1524, 1988
34. Wan, et al., "Der p 1 facilitates transepithelial allergen delivery by disruption of tight junctions", *The Journal of Clinical Investigation*, Vol. 104, No. 1, pp. 123-133, 1999
35. Haapasalo, et al., "Degradation of basement membrane collagen by proteases from some anaerobic oral microorganisms", *Oral Microbiol. Immunol.*, 3:97-102, 1988
36. Smalley, et al, "The degradation of type I collagen and human plasma fibronectin by the trypsin-like enzyme and extracellular membrane vesicles of Bacteroides Gingivalis W50", *J. Arch. Oral Biol.*, Vol. 33 (5), pp. 323-329, 1988
37. Shah, et al., "Assessment of the Relative Cytotoxicity of Porphyromonas gingivalis Cells, Products, and Components on Human Epithelial Cell Lines", *J. Periodontol.*, Vol. 63, No. 1, pp. 44-51, 1992
38. Mizejewski, "Role of Integrins in Cancer: Survey of Expression Patterns", *Integrins Expression in Cancer*, Vol. 222, pp. 124-138, 1999
39. Velasco-Velazquez, et al., "Integrins and integrin-associated molecules: Targets for the development of antimetastatic therapies", *Rev. Invest. Clin.*, 51(3):183-93, 1999
40. Scragg, et al., "Targeted disruption of Fibronectin-Integrin Interactions in Human Gingival Fibroblasts by the RI Protease of Porphyromonas gingivalis W50", *Infection and Immunity*, Vol. 67, No. 4, pp. 1837-1843, 1999
41. Johansson, et al., "Characterization of the proteinase-dependent cytotoxicity of Porphyromonas gingivalis", *Eur. J. Oral Sci.*, 106, pp. 863-871, 1998
42. Katz, et al., "Characterization of Porphyromonas gingivalis-Induced Degradation of Epithelial Cell Junctional Complexes", *Infection and Immunity*, Vol. 68, No. 3, pp. 1441-1449, 2000
43. Chen, et al, "Protease-Active Extracellular Protein Preparations from Porphyromonas gingivalis W83 Induce N-Cadherin Proteolysis, Loss of Cell Adhesion, and Apoptosis in Human Epithelial Cells", *J. Periodontol.*, Vol. 72, No. 5, pp. 641-650, 2001
44. Layman, et al., "Suppression of Fibroblast Growth by Bacteroides gingivalis Endotoxin is not Reduced by Serum Lipoproteins", *J. Periodontol.*, Vol. 60, No. 5, pp. 259-263, 1989
45. Layman, et al., "Growth Inhibitory Effects of Endotoxins from Bacteroides gingivalis and intermedius on Human Gingival Fibroblasts in vitro", *J. Periodontol.*, Vol. 58, No. 6, pp. 387-392, 1987
46. Chen, et al., "Cleavage of N-Cadherin by extracellular proteases from Porphyromonas gingivalis", *J. Dent. Res.*, 79 (IADR Abstracts), Abstract No. 706, 2000
47. Josephson, *Biological Solvent for Killing Tumors*, *Mod. Drug Disc.*, p. 16, March 2000


EXAMINER

Guaranteed

DATE CONSIDERED

3/5/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 02-192	Serial No. 09/849,115
		SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		RECEIVED JUN 26 2002	
		Applicant: Progulske-Fox, et al.		TECH CENTER 1600/2900	
		Filing Date: May 5, 2001	Group: 1645		

U.S. PATENT DOCUMENTS



Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation	
					Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

1.	Fidler, et al., "The Implications of Angiogenesis for the Biology and Therapy of Cancer Metastasis", <i>Cell</i> , Vol. 79, p. 185-188, minireview, 1994
2.	O'Reilly, et al., "Angiostatin: A Novel Angiogenesis Inhibitor that Mediates the Suppression of Metastases by a Lewis Lung Carcinoma", <i>Cell</i> , Vol. 79, p. 315-328, 1994
3.	Aducse-Opoku, et al., "The Tla Protein of Porphyromonas gingivalis W50: a Homolog of the RI Protease Precursor (PrpRI) is an Outer Membrane Receptor Required for Growth on Low Levels of Hemin", <i>Journal of Bacteriology</i> , Vol. 179, No. 15, p. 4778-4788, 1997
4.	Nishikata, et al., "Characterization of Porphyromonas (Bacteroides) Gingivalis Hemagglutinin as a Protease", <i>Biochemical and Biophysical Research Communications</i> , Vol. 178, No. 1, p. 336-342, 1991
5.	Hashizume, et al., "Openings between Defective Endothelial Cells Explain Tumor Vessel Leakiness", <i>American Journal of Pathology</i> , Vol. 156, No. 4, p. 1363-1380, 2000
6.	Yeh, et al., "Rhodostomin, A Snake Venom Disintegrin, Inhibits Angiogenesis Elicited by Basic Fibroblast Growth Factor and Suppresses Tumor Growth by a Selective $\alpha_v\beta_3$ Blockade of Endothelial Cells", <i>Molecular Pharmacology</i> , Vol. 59, No. 5, p. 1333-1342, 2001
7.	Rangarajan, et al., "The prpR1 and prR2 arginine-specific protease genes of Porphyromonas gingivalis W50 produce five biochemically distinct enzymes", <i>Molecular Microbiology</i> , 23(5), p. 955-965, 1997
8.	Herlyn, "Endothelial Cells as Targets for Tumor Therapy", Editorial, <i>Journal of Immunotherapy</i> , 22(3):185, 1999

	9. ¹ Curtis, et al., "Molecular genetics and nomenclature of proteases of <i>Porphyromonas gingivalis</i> ", <i>J. Periodont. Res.</i> , 34, pp. 464-472, 1999	
	10. ¹ Han, et al., "The Hemagglutinin Gene A (<i>hagA</i>) of <i>Porphyromonas gingivalis</i> 381 contains four Large, Contiguous, Direct Repeats", <i>Infection and Immunity</i> , Vol. 64, No. 10, p. 4000-4007, 1996	
	11. ¹ GenBank Accession number X82680	
	12. ¹ GenBank Accession number U15282	
	13. ^h GenBank Accession number D26470	
	14. ¹ GenBank Accession number L26341	
	15. ¹ GenBank Accession number L27483	
	16. ¹ GenBank Accession number AF026946	
	17. ¹ GenBank Accession number A55426	
	18. ¹ GenBank Accession number AF007124	
	19. ¹ GenBank Accession number U85038	
	20. ¹ GenBank Accession number D64081	
	21. ¹ GenBank Accession number U75366	
	22. ¹ GenBank Accession number U54691	
	23. ¹ GenBank Accession number D83258	
	24. ¹ GenBank Accession number U42210	
	25. ¹ GenBank Accession number AF017059	
	26. ¹ GenBank Accession number U68468	
	27. ¹ GenBank Accession number Y07618	
	28. ¹ GenBank Accession number S75942	
	29. ¹ GenBank Accession number M83096	
	EXAMINER	DATE CONSIDERED
		3/04/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-192

Serial No.

09/849,115

**SECOND SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use several sheets if necessary)



RECEIVED

SEP 30 2002

Applicant:

Progulske-Fox, et al.

TECH CENTER 1600/2900

Filing Date:

May 5, 2001

Group:

1645

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclasses	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

1. Potempa, et al., "The Multiple Forms of Trypsin-like Activity Present in Various Strains of *Porphyromonas gingivalis* are due to the Presence of either Arg-Gingipain or Lys-Gingipain", *Infection and Immunity*, Vol. 63, No. 4, pp. 1176-1182, 1995

EXAMINER

Gambir

DATE CONSIDERED

3/5/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.